Affiliation:
1. Alzheimer’s Therapeutic Research Institute, Department of Neurology, Keck School of Medicine of USC, Los Angeles, California, USA
Abstract
Abstract
Objective
The Alzheimer’s Therapeutic Research Institute (ATRI) developed a novel clinical data management system, the ATRI electronic data capture system (ATRI EDC), to address the complex regulatory, operational, and data requirements that arise in the conduct of multicenter Alzheimer’s disease and Alzheimer’s disease-related dementias (AD/ADRDs) clinical trials. We describe the system, its utility, and the broader implications for the field of clinical trials and clinical research informatics.
Materials and Methods
The ATRI EDC system was developed, tested, and validated using community-based agile software development methods and cloud-native single-page application design principles. It offers an increasing number of application modules, supports a high degree of study-specific configuration, and empowers study teams to effectively communicate and collaborate on the accurate and timely completion of study activities.
Results
To date, the ATRI EDC system supports 10 clinical studies, collecting study data for 4596 participants. Three case descriptions further illustrate how the system’s capabilities support diverse study-specific requirements.
Discussion
The ATRI EDC system has several advantages: its modular capabilities can accommodate rapidly evolving research designs and technologies; its community-based agile development approach and community-friendly licensing model encourage collaboration per the principles of open science; finally, with continued development and community building efforts, the system has the potential to facilitate the effective conduct of clinical studies beyond the field of AD/ADRD.
Conclusion
By effectively addressing the requirements of multicenter AD/ADRD studies, the ATRI EDC system supports ATRI’s scientific mission of rigorously testing new AD/ADRD therapies and facilitating the effective conduct of multicenter clinical studies.
Funder
National Institute on Aging
Publisher
Oxford University Press (OUP)
Reference30 articles.
1. 2020 Alzheimer’s disease facts and figures;Alzheimers Dement,2020
2. Alzheimer’s disease drug development pipeline: 2020;Cummings;Alzheimers Dement (N Y),2020
3. The A4 study: stopping AD before symptoms begin?;Sperling;Sci Transl Med,2014
4. Using digital tools to advance Alzheimer’s drug trials during a pandemic: the EU/US CTAD Task Force;Kaye;J Prev Alz Dis,2021
5. Adaptive platform trials: definition, design, conduct and reporting considerations;The Adaptive Platform Trials Coalition;Nat Rev Drug Discov,2019
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献